Barriers to pediatric lead screening: implications from a web-based survey of Vermont pediatricians

Britton Keeshan1, Catherine Avener, Amanda Abramson

  • 1University of Vermont, Burlington, VT, USA. britton.keeshan@uvm.edu

Clinical Pediatrics
|February 13, 2010
PubMed

Insights

Pediatricians screened fewer children for lead exposure than recommended. Lower screening rates were linked to beliefs about dangerous blood lead levels (BLL) and practice location, highlighting a need for targeted interventions.

Area of Science:

  • Pediatric Public Health
  • Environmental Health
  • Epidemiology

Background:

  • Lead exposure poses significant risks to child health.
  • The Vermont Department of Health (VDH) recommends universal blood lead level (BLL) screening for 12- and 24-month-old children.
  • Screening rates in Vermont fell short of recommendations in 2006.

Purpose of the Study:

  • To identify barriers preventing pediatricians from performing recommended blood lead screening.
  • To compare factors associated with higher and lower screening rates among Vermont pediatricians.

Main Methods:

  • A survey was distributed to Vermont primary care pediatricians.
  • Pediatricians were categorized into higher and lower screening groups.
  • Statistical analysis, including odds ratios and confidence intervals, was used to identify determinants of lower screening rates.

Main Results:

  • Pediatricians perceiving negative health outcomes starting at BLL >10 microg/dL were more likely to be lower screeners (OR = 3.64).
  • Practicing in Chittenden County (OR = 3.34) and disagreeing with VDH recommendations (OR = 4.90) were also associated with lower screening.
  • Adjusted analysis revealed male gender, a perceived dangerous BLL threshold of >10 microg/dL, and a low self-reported Medicaid population were significant determinants of lower screening.

Conclusions:

  • Physician perception of dangerous blood lead levels (BLL) at >10 microg/dL is a significant barrier to screening.
  • Targeted educational initiatives by the VDH emphasizing risks associated with BLL < or = 10 microg/dL could increase screening rates.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Preventive Healthcare Services01:30

Preventive Healthcare Services

Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include: